3-氯噻吩-2-羧酸甲酯 | 88105-17-3

• 物质功能分类: 医药中间体 - 噻吩类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-氯噻吩-2-羧酸甲酯
• 中文别名: 3-氯噻吩-2-甲酸甲酯
• 英文名称: methyl 3-chlorothiophene-2-carboxylate
• CAS: 88105-17-3
• 化学式: C₆H₅ClO₂S
• mdl: MFCD00068135
• 分子量: 176.624
• InChiKey: ZWKYYONTMGVPSP-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38°C
• 沸点：
  72-74°C 0,2mm
• 密度：
  1.28
• 闪点：
  72-74°C/0.2mm
• 稳定性/保质期：

  按规定使用和贮存的这些物质不会分解，也能够避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• TSCA：
  N
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

SDS

Name:	Methyl 3-chlorothiophene-2-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	88105-17-3

Section 1 - Chemical Product MSDS Name:Methyl 3-chlorothiophene-2-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
88105-17-3	Methyl 3-chlorothiophene-2-carboxylate	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 88105-17-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 30 - 31 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5ClO2S
Molecular Weight: 177

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 88105-17-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 3-chlorothiophene-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 88105-17-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 88105-17-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 88105-17-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

危险品标志

此物质会造成皮肤刺激，严重眼刺激，并可能引起呼吸道刺激。若吸入，请立即将患者移至空气新鲜处；如皮肤接触到该物质，请脱去受污染的衣物，用肥皂和清水彻底清洗受影响区域；如有不适感，应立即就医。如眼睛接触，需分开眼睑并用流动清水或生理盐水冲洗，并立即寻求医疗帮助；若吞食，则应立即漱口，禁止催吐，并及时就医。

对于救援者的建议：将患者转移到安全地点，并咨询医生。在条件允许的情况下，请提供化学品安全技术说明书给现场医生参考。

泄漏处理

少量泄漏时，尽量收集液体并将其存入可密封的容器中；使用沙土、活性炭或其他惰性材料吸收残留物质，并移至安全区域，禁止将废液排入下水道。大量泄漏时，请筑堤收容或挖掘沟渠储存泄漏物，并封闭排水管道；用泡沫覆盖以减少蒸发，使用防爆泵将泄漏物转移至槽车或专用收集器内，并在适当条件下回收或送至废物处理场所处置。

应用

作为医药中间体用于合成其他杂环类化合物：

1. 合成噻吩并[3,4-b]噻吩-苯并二噻吩三元共聚物；
2. 合成苯丙杂环化合物。

反应信息

• 作为反应物：
  描述：

  3-氯噻吩-2-羧酸甲酯 在 sodium hydroxide 、 氯化亚砜 、 水 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 3-氯噻吩-2-甲酰氯
  参考文献：
  名称：

  Eller, Gernot A.; Haring, Andreas W.; Datterl, Barbara, Heterocycles, 2007, vol. 71, # 1, p. 87 - 104

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨基-2-噻吩甲酸甲酯 在 亚硝酸特丁酯 、 copper dichloride 作用下， 以 乙腈 、 乙二醇 为溶剂， 以54%的产率得到3-氯噻吩-2-羧酸甲酯
  参考文献：
  名称：

  沙梅尔反应从间歇到连续过程的高效换位

  摘要：

  研究了桑德迈尔氯化法从批次到安全连续流过程的转换。我们最初的方法是开发一种使用流化学的级联方法，该方法涉及重氮盐的生成并用氯化铜淬灭。为了实现这种安全的连续过程重氮化，使用了化学计量方法（Simplex方法）并外推以建立完全连续流方法。还通过合成几种（杂）芳基氯来检查反应范围。还对过程进行了验证和放大。在提高安全性的同时获得了更高的生产率。

  DOI：

  10.1021/acs.oprd.6b00318

文献信息

• Novel fused pyrrolocarbazoles
  申请人：Hudkins L. Robert

  公开号：US20050143442A1

  公开（公告）日：2005-06-30

  The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.

  本发明一般涉及选定的融合吡咯咯噻唑，包括其药物组合物以及用于治疗疾病的方法。本发明还涉及制备这些融合吡咯咯噻唑的中间体和方法。
• PESTICIDAL COMPOSITIONS
  申请人：Parker Marshall H.

  公开号：US20120053146A1

  公开（公告）日：2012-03-01

  Molecules according to Formula One: and their uses are disclosed herein.

  根据公式一的分子的使用在本文件中披露。
• Novel IDO inhibitors and methods of use thereof
  申请人：Prendergast C. George

  公开号：US20070105907A1

  公开（公告）日：2007-05-10

  Novel indoleamine 2,3-dioxygenase (IDO) inhibitors, compositions comprising the same, and methods of use thereof are disclosed.

  披露了新型的吲哚胺2,3-双加氧酶（IDO）抑制剂，包含该抑制剂的组合物以及使用它们的方法。
• [EN] CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]<br/>[FR] THIAZOLES SUBSTITUÉS PAR CARBOXAMIDE OU SULFONAMIDE ET DÉRIVÉS APPARENTÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR NUCLÉAIRE ORPHELIN ROR[GAMMA]
  申请人：PHENEX PHARMACEUTICALS AG

  公开号：WO2013178362A1

  公开（公告）日：2013-12-05

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  这项发明提供了用于孤儿核受体RORγ的调节剂，以及通过向需要的人类或哺乳动物投与这些新型RORγ调节剂来治疗RORγ介导的疾病的方法。具体而言，本发明提供了含有环状化合物的羧酰胺或磺酰胺的化合物的公式（1）、（1'）、（100）、（100'）、（200）和（200'）及其对映体、二对映体、互变异构体、/V-氧化物、溶剂合物和药用可接受盐。
• Inhibitors of protein tyrosine phosphatase 1B
  申请人：Lee Jinbo

  公开号：US20050203081A1

  公开（公告）日：2005-09-15

  Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.

  蛋白质酪氨酸磷酸酶（PTPases），如PTP1B，在调节广泛的细胞反应，如胰岛素信号传导中发挥作用。取代的并环融合噻吩化合物可以抑制PTP1B，从而增加胰岛素敏感性。因此，PTP1B的抑制可以提供一种治疗PTPase介导的疾病，如糖尿病的替代方法。